The Association between Serum Follistatin-like Proteins and Cardiovascular Diseases: A Systematic Review and Meta-analysis.

Autor:	Ahmadzadeh AM; Transplant Research Center, Clinical Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.; Department of Radiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran., Khodashahi R; Transplant Research Center, Clinical Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.; Clinical Research Development Unit, Imam Reza Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran., Shabestari MM; Department of Cardiology, Emam Reza Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran., Aliakbarian M; Transplant Research Center, Clinical Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.; Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran., Sahebkar A; Center for Global Health Research, Saveetha Medical College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India.; Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.; Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran., Arjmand MH; Transplant Research Center, Clinical Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Jazyk:	angličtina
Zdroj:	Current cardiology reviews [Curr Cardiol Rev] 2024; Vol. 20 (6), pp. e180724231994.
DOI:	10.2174/011573403X304195240715103930
Abstrakt:	Background: Follistatin-like proteins (FSTLs) are adipomyokines secreted by adipocytes and myocytes. Previous studies have reported an increase in circulating FSTL1 levels in response to cardiovascular injuries. In this study, we conducted a systematic review and metaanalysis to assess the association between circulating FSTLs and Cardiovascular Diseases (CVDs). Methods: We performed a comprehensive literature search using PubMed, Web of Science, Scopus, and Embase databases. After screening the articles, we selected eligible studies, extracted relevant data, and calculated the pooled Standardized Mean Difference (SMD). We also conducted a sensitivity analysis to identify sources of heterogeneity and assessed publication bias. Results: Among the 577 articles initially retrieved, we included 5 studies comprising a total of 941 cases with CVDs and 446 controls. All included studies measured FSTL1 levels. The pooled SMD analysis revealed a significant difference in circulating FSTL1 levels between subjects with CVDs and control groups (SMD = 0.853, 95% CI = 0.158-1.548, P = 0.016). Heterogeneity was primarily attributed to a single study that measured FSTL1 levels in heart failure patients with preserved ejection fraction. No publication bias was observed. Conclusion: Our findings demonstrate significantly higher levels of FSTL1 in patients with CVD compared to control subjects. This suggests that FSTL1 may have potential as a diagnostic and prognostic biomarker in CVDs. However, further well-designed studies are needed to validate its clinical utility. (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu